ASM INTERNATIONAL N.V. REPORTS FIRST QUARTER 2022 RESULTS
Almere, The Netherlands
April 20, 2022, 6 p.m. CET
ASM International N.V. (Euronext Amsterdam: ASM) today reports its first quarter 2022 operating results (unaudited).
Record high revenue and orders in Q1, continued revenue growth expected for the rest of the year
|EUR million||Q1 2021||Q4 2021||Q1 2022|
|YoY change % as reported / at constant currencies||23 % / 31 %||70 % / 70 %||72 % / 65 %|
|YoY change % as reported / at constant currencies||21 % / 29 %||42 % / 40 %||31 % /25 %|
|Gross profit margin %||49.5 %||47.0 %||47.8 %|
|Operating result margin %||31.6 %||26.7 %||27.7 %|
|Share in income of investments in associates (excluding amortization intangible assets resulting from the sale of ASMPT stake in 2013)||13.9||25.8||23.7|
|Amortization intangible assets (resulting from the sale of ASMPT stake in 2013)||(3.0)||(3.2)||(3.2)|
|Normalized net earnings (excluding amortization intangible assets resulting from the sale of ASMPT stake in 2013 and result from sale of ASMPT shares)||125.5||138.1||145.7|
- New orders of €706 million for the first quarter 2022 increased by 65% at constant currencies compared to the same period last year (72% as reported).
- Year-on-year revenue growth for the first quarter 2022 was €25% at constant currencies (31% as reported).
- Gross profit margin of 47.8% in the first quarter 2022 was lower compared to 49.5% in the same quarter last year which reflected an exceptionally strong mix.
- Operating result for the first quarter 2022 improved from €125 million last year to €143 million this year driven again by strong revenue growth.
- Normalized net earnings for the first quarter 2022 were €146 million.
“ASM started the year with a strong performance, with again record quarterly levels of orders, revenue and results,” said Benjamin Loh, President and Chief Executive Officer of ASM International. “In the first quarter, our company delivered revenue of €517 million, an increase of 25% at constant currencies and in line with our guidance of €500-530 million, successfully navigating ongoing challenging supply chain conditions. The demand environment continued to be very robust. Our Q1 order intake increased year-on-year by 65% at constant currencies to €706 million. While orders were again led by record high logic/foundry demand, momentum was also strong in memory, and in the power/analog and wafer maker segments. We further stepped up investments to drive the growth of our company and at the same time delivered a solid 15% increase in operating profits in the first quarter, and a strong free cash flow of €99 million (excluding the acquisition of Reno)."
Supply chain conditions are expected to remain tight in the second quarter. For Q2 at constant currencies, we expect revenue of €540-570 million, in line with our previous forecast for a further sequential increase in Q2. Based on the current visibility, we expect revenue in the second half of 2022 to be clearly higher than the level in the first half, to a certain extent depending on the pace of improvement in supply chain conditions. Expectations are unchanged for the wafer fab equipment to increase by a mid to high teens percentage in 2022, a level which we are confident to outperform this year.
ANNUAL GENERAL MEETING OF SHAREHOLDERS
On April 1, 2022, ASMI published the agenda for the 2022 Annual General Meeting of Shareholders (AGM), to be held on May 16, 2022, which, as also earlier announced, includes amongst others, the proposals to:
- appoint Mr. Hichem M’Saad as additional member of the Management Board;
- change the remuneration policy for the Management Board and Supervisory Board;
- re-appoint Mr. Marc de Jong as member of the Supervisory Board;
- declare a regular dividend of €2.50 per common share over 2021; and
- approve the annual accounts of 2021.
Please refer to the AGM documents available on our website for more detailed information.
About ASM International
ASM International N.V., headquartered in Almere, the Netherlands, and its subsidiaries design and manufacture equipment and process solutions to produce semiconductor devices for wafer processing, and have facilities in the United States, Europe, and Asia. ASM International's common stock trades on the Euronext Amsterdam Stock Exchange (symbol ASM). For more information, visit ASMI's website at www.asm.com.
Cautionary Note Regarding Forward-Looking Statements: All matters discussed in this press release, except for any historical data, are forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These include, but are not limited to, economic conditions and trends in the semiconductor industry generally and the timing of the industry cycles specifically, currency fluctuations, corporate transactions, financing and liquidity matters, the success of restructurings, the timing of significant orders, market acceptance of new products, competitive factors, litigation involving intellectual property, shareholders or other issues, commercial and economic disruption due to natural disasters, terrorist activity, armed conflict or political instability, changes in import/export regulations, epidemics and other risks indicated in the Company's reports and financial statements. The Company assumes no obligation nor intends to update or revise any forward-looking statements to reflect future developments or circumstances.
This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
ASM International N.V will host an investor conference call and webcast on Thursday, April 21, 2022, at 3:00 p.m. Continental European Time (9:00 a.m. – US Eastern Time).
Conference call participants should pre-register using the link below to receive the Dial-In Numbers, Direct Event Passcode and unique Registrant ID, which will be needed to access the conference call.
Online registration for the conference call: http://emea.directeventreg.com/registration/9926845
A simultaneous audio webcast and replay will be accessible at www.asm.com.
Investor and media contact:
T: +31 88 100 8500
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Mandalay Resources Corporation Announces the Results of Its Annual General Meeting of Shareholders25.5.2022 23:32:49 CEST | Press release
TORONTO, May 25, 2022 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND, OTCQB: MNDJF) is pleased to announce the results of its Annual General Meeting of Shareholders (the “Meeting”) held today virtually. All the resolutions presented at the Meeting were approved by the shareholders, with the votes cast by proxy representing 67.63% of the total shares outstanding as of the record date. Election of Directors The number of directors was fixed at seven members and each of the seven nominees listed in the Company’s Management Information Circular dated April 14, 2022, were re-elected to the Company’s Board of Directors. Abraham Jonker remains the lead independent director and Bradford Mills continues as Chair. Results of the votes cast by proxy are set out below. ResolutionVotes Cast by Proxy For% ForVotes Cast by Proxy Withheld% WithheldBradford A. Mills61,552,12099.95329,1930.047Abraham Jonker61,551,31399.95130,0000.049Amy Freedman61,547,53899.94
Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress25.5.2022 22:01:00 CEST | Press release
Celebrating EULAR’s 75thanniversary with focus on a new era of rheumatoid arthritis care Mechelen, Belgium;25 May 2022, 22.01CET;Galapagos NV (Euronext & Nasdaq: GLPG) will present 11 abstracts at the European League Against Rheumatism (EULAR) congress 2022, 01-04 June, taking place in Copenhagen, Denmark. The broad range of abstracts include trial data analyses supporting the efficacy and safety profile of filgotinib andreal-world clinical data around alignment of prescribing between physicians and rheumatoid arthritis (RA) patients. Galapagos is also hosting a hybrid symposium: “Evolving patient care in RA: Can JAK inhibitors meet patient and physician expectations for RA treatment?”, which will include a discussion focused on aligning physician and patient treatment goals, looking at what is meant by ‘comprehensive care’ and how to ensure that people living with RA are part of treatment and care goal setting. A meet-the-expert session, “Patient-centred care in RA: cutting through th
trivago N.V. Announces Annual General Meeting of Shareholders25.5.2022 21:39:06 CEST | Press release
trivago N.V. (NASDAQ: TRVG) announced today that its annual general meeting of shareholders will be held on June 30, 2022 at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands. The meeting will start at 3:00 p.m. CEST. The convening notice and explanatory notes for the general meeting are available free of charge in the Investor Relations section of trivago N.V.'s corporate website at ir.trivago.com. About trivago N.V. trivago is a leading global hotel search platform focused on reshaping the way travelers search for and compare hotels and alternative accommodations. Incorporated in 2005 in Düsseldorf, Germany, the platform allows travelers to make informed decisions by personalizing their hotel search and providing them access to a deep supply of hotel information and prices. trivago enables its advertisers to grow their businesses by providing access to a broad audience of travelers via its websites and apps. As of March 31, 2022, trivago has est
Correction: Changes in Nokia Corporation's own shares25.5.2022 19:20:00 CEST | Press release
Nokia Corporation Stock Exchange Release 25 May 2022 at 20:20 EEST Correction: Changes in Nokia Corporation's own shares Espoo, Finland – This is a correction to "Changes in Nokia Corporation's own shares" stock exchange release that was published today at 19:30 EEST. A total of 183 965 Nokia shares (NOKIA) held by the company were today transferred without consideration to participants of Nokia's equity-based incentive plans in accordance with the rules of the plans. The transfer is based on the resolution of the Board of Directors to issue shares held by the company to settle its commitments to participants of the plans as announced on 3 February 2022. The number of own shares held by Nokia Corporation following the transfer is 61 262 561. This version is otherwise identical but now includes an updated total number of Nokia shares transferred (incorrect number was 188 636). About Nokia At Nokia, we create technology that helps the world act together. As a trusted partner for critical
Ultimovacs’ Clinical Data in Journal for ImmunoTherapy of Cancer Show Long-term Dynamic T Cell Responses with UV1 and Checkpoint Inhibitor Synergy25.5.2022 18:45:00 CEST | Press release
Data from three trials of UV1 show dynamic T cell responses, lasting up to 7.5 years UV1-specific immune responses associated with longer clinical survivalSynergy between UV1 vaccination and checkpoint inhibition Oslo, 25 May2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced the publication of long-term follow-up data on UV1 in the Journal for ImmunoTherapy of Cancer (JITC). The data show that dynamic UV1 specific immune responses last up to 7.5 years, are associated with longer survival and are enhanced when UV1 is used in combinations with checkpoint inhibitors. “It is important to be able to share this validating data with our research and clinical colleagues through JITC. The data demonstrate highly durable UV1-induced immune responses that are associated with substantially longer overall survival and boosted by checkpoint inhibitors. This is strong support for Ultimovacs’ broad Phase II program combining UV1